232 related articles for article (PubMed ID: 28417242)
1. Combined use of the multidimensional prognostic index (MPI) and procalcitonin serum levels in predicting 1-month mortality risk in older patients hospitalized with community-acquired pneumonia (CAP): a prospective study.
Pilotto A; Dini S; Daragjati J; Miolo M; Mion MM; Fontana A; Storto ML; Zaninotto M; Cella A; Carraro P; Addante F; Copetti M; Plebani M
Aging Clin Exp Res; 2018 Feb; 30(2):193-197. PubMed ID: 28417242
[TBL] [Abstract][Full Text] [Related]
2. Multidimensional Prognostic Index and pro-adrenomedullin plasma levels as mortality risk predictors in older patients hospitalized with community-acquired pneumonia: a prospective study.
Pilotto A; Dini S; Veronese N; Daragjati J; Miolo M; Mion MM; Fontana A; Lo Storto M; Zaninotto M; Bragato G; Cella A; Carraro P; Addante F; Copetti M; Plebani M
Panminerva Med; 2018 Sep; 60(3):80-85. PubMed ID: 29546738
[TBL] [Abstract][Full Text] [Related]
3. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia.
Ugajin M; Yamaki K; Hirasawa N; Yagi T
Respir Care; 2014 Apr; 59(4):564-73. PubMed ID: 24170911
[TBL] [Abstract][Full Text] [Related]
4. Serial procalcitonin levels for predicting prognosis in community-acquired pneumonia.
Ito A; Ishida T; Tachibana H; Ito Y; Takaiwa T
Respirology; 2016 Nov; 21(8):1459-1464. PubMed ID: 27398948
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of a semi-quantitative procalcitonin test and the A-DROP Japanese prognostic scale for predicting mortality among adults hospitalized with community-acquired pneumonia.
Kasamatsu Y; Yamaguchi T; Kawaguchi T; Tanaka N; Oka H; Nakamura T; Yamagami K; Yoshioka K; Imanishi M
Respirology; 2012 Feb; 17(2):330-6. PubMed ID: 22059525
[TBL] [Abstract][Full Text] [Related]
6. Short- and longer-term predictive capacity of the Multidimensional Prognostic Index: The timing of the assessment is of no consequence.
De Luca E; Perissinotto E; Fabris L; Pengo V; Zurlo A; De Toni P; De Zaiacomo F; Manzato E; Giantin V
Arch Gerontol Geriatr; 2015; 61(3):458-63. PubMed ID: 26306454
[TBL] [Abstract][Full Text] [Related]
7. The value of procalcitonin level in community-acquired pneumonia in the ED.
Park JH; Wee JH; Choi SP; Oh SH
Am J Emerg Med; 2012 Sep; 30(7):1248-54. PubMed ID: 22030193
[TBL] [Abstract][Full Text] [Related]
8. The utility of serial procalcitonin measurements in addition to pneumonia severity scores in hospitalised community-acquired pneumonia: A multicentre, prospective study.
Ito A; Ito I; Inoue D; Marumo S; Ueda T; Nakagawa H; Taki M; Nakagawa A; Tatsumi S; Nishimura T; Shiota T; Ishida T
Int J Infect Dis; 2020 Mar; 92():228-233. PubMed ID: 31981766
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification and prediction value of procalcitonin and clinical severity scores for community-acquired pneumonia in ED.
Zhou H; Guo S; Lan T; Ma S; Zhang F; Zhao Z
Am J Emerg Med; 2018 Dec; 36(12):2155-2160. PubMed ID: 29691103
[TBL] [Abstract][Full Text] [Related]
10. The multidimensional prognostic index predicts short- and long-term mortality in hospitalized geriatric patients with pneumonia.
Pilotto A; Addante F; Ferrucci L; Leandro G; D'Onofrio G; Corritore M; Niro V; Scarcelli C; Dallapiccola B; Franceschi M
J Gerontol A Biol Sci Med Sci; 2009 Aug; 64(8):880-7. PubMed ID: 19349589
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia.
Horie M; Ugajin M; Suzuki M; Noguchi S; Tanaka W; Yoshihara H; Kawakami M; Kichikawa Y; Sakamoto Y
Am J Med Sci; 2012 Jan; 343(1):30-5. PubMed ID: 22207498
[TBL] [Abstract][Full Text] [Related]
12. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.
Krüger S; Ewig S; Marre R; Papassotiriou J; Richter K; von Baum H; Suttorp N; Welte T;
Eur Respir J; 2008 Feb; 31(2):349-55. PubMed ID: 17959641
[TBL] [Abstract][Full Text] [Related]
13. Procalcitonin, a valuable biomarker assisting clinical decision-making in the management of community-acquired pneumonia.
Lindstrom ST; Wong EK
Intern Med J; 2014 Apr; 44(4):390-7. PubMed ID: 24528892
[TBL] [Abstract][Full Text] [Related]
14. Performance of pro-adrenomedullin for identifying adverse outcomes in community-acquired pneumonia.
España PP; Capelastegui A; Mar C; Bilbao A; Quintana JM; Diez R; Esteban C; Bereciartua E; Unanue U; Uranga A
J Infect; 2015 May; 70(5):457-66. PubMed ID: 25499199
[TBL] [Abstract][Full Text] [Related]
15. The usefulness of serum procalcitonin, C-reactive protein, soluble triggering receptor expressed on myeloid cells 1 and Clinical Pulmonary Infection Score for evaluation of severity and prognosis of community-acquired pneumonia in elderly patients.
Wang Y; Zhang S; Li L; Xie J
Arch Gerontol Geriatr; 2019; 80():53-57. PubMed ID: 30366226
[TBL] [Abstract][Full Text] [Related]
16. YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia.
Spoorenberg SM; Vestjens SM; Rijkers GT; Meek B; van Moorsel CH; Grutters JC; Bos WJ;
Respirology; 2017 Apr; 22(3):542-550. PubMed ID: 27782361
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia.
Claessens YE; Mathevon T; Kierzek G; Grabar S; Jegou D; Batard E; Loyer C; Davido A; Hausfater P; Robert H; Lavagna-Perez L; Bernot B; Plaisance P; Leroy C; Renaud B
Intensive Care Med; 2010 May; 36(5):799-809. PubMed ID: 20232049
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis.
Liu D; Su LX; Guan W; Xiao K; Xie LX
Respirology; 2016 Feb; 21(2):280-8. PubMed ID: 26662169
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of procalcitonin in community-acquired pneumonia.
Schuetz P; Suter-Widmer I; Chaudri A; Christ-Crain M; Zimmerli W; Mueller B;
Eur Respir J; 2011 Feb; 37(2):384-92. PubMed ID: 20595156
[TBL] [Abstract][Full Text] [Related]
20. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia.
Zhydkov A; Christ-Crain M; Thomann R; Hoess C; Henzen C; Werner Z; Mueller B; Schuetz P;
Clin Chem Lab Med; 2015 Mar; 53(4):559-66. PubMed ID: 25014522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
